Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trump Win Is False Security For Drug Makers, Allergan CEO Warns

Executive Summary

Industry should act on drug pricing now while there is a post-election reprieve, Allergan CEO Brent Saunders said during the Forbes Healthcare Summit. Trump is a populist who will jump on the next big pricing scandal, he said.


Related Content

Saunders: Industry Must Act Before We Lose Champions For Innovation In Congress
The Bully Pulpit: Trump Versus Drug Prices
Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan
What Does 2017 Hold For Pharma?
Expect Industry To Step Up Drug Pricing Self-Regulation In 2017 – PwC
Podcast: The Price is Right – HHS Transition And Next FDA Commissioner?
Trump’s HHS, CMS Leadership Choices Underscore Focus On ACA Reform
Drug Affordability Review By National Academies Kicks Off With Lower Profile Than Expected
Trump’s Election Could Bring ‘Best Of Times’ For Pharma
Allergan's Price Reform Pledge: Will Others Follow?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts